| Population name | Medetalibeyoglu |
| Genome | not specified |
| Consortium | University of Istanbul |
| Super population | SAS |
| Population description | The patients were included between April–June 2020 that admitted to the COVID-19 center of a single university hospital with a number of criteria used to determine severe vs mild cases. |
| Population origin | Istanbul, Turkey |
| Case population size | 284 |
| Control population size | 100 |
| Comorbidities | Hypertension 72 (24.5%), Diabetes mellitus 36 (12.7%), Chronic obstructive pulmonary disease 30 (10.6%), Coronary artery disease 17 (6.0%), Congestive heart failure 5 (1.8%), Solid malignancy 26 (9.2%), Hematological malignancy 7 (2.5%) |
| Mean / median age | 49 |
| Sex | 45.1% Female |
| Severity | Severe |
| Sample source | Whole blood |
| Method | DNA was extracted from the collected blood by using the Genemark isolation kit (Genemark, USA). PCR was used to amplify the MBL2 gene and a restriction enzyme BanI was used to identify the codon 54 polymorphism. All of the patients and controls were examined for the codon 54 A/B (gly54asp: rs1800450) variation in exon 1 of the MBL2 gene. |
| Bioinformatics | IBM SPSS version 21.0 was used for statistical analysis. Multivariate binary logistic regression analyses to find out the association between different genetic variants of the MBL2 gene with study parameters. The results were adjusted for age and sex. Statistical significance was accepted as p < 0.05 for the results of all analyses. |
| Imputation details | NA |
| Limitations | a. Small population size, statistical inference is limited |